Refine by
Pharmaceutical And Medical Technology Articles & Analysis
46 news found
Introduction The pharmaceutical industry demands absolute precision, reliability, and safety throughout every stage of production. Whether manufacturing life-saving medicines or performing sensitive research, facilities must maintain strict control over environmental conditions. One often overlooked but essential component is gas analysis. Gases such as oxygen, nitrogen, and carbon dioxide play ...
In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. ...
Shanghai, China – June 14, 2024 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services for Active Pharmaceutical Ingredients (APIs) and intermediates, is excited to announce its participation in CPHI China 2024. The event will take place from June 19 to 21, 2024, at the Shanghai New ...
[Cambridge, June 8, 2024] Protheragen-ING is pleased to announce its participation in the 26th SAPA-NE Annual Conference. The event will be held at the Cambridge Marriott Boston (50 Broadway, Cambridge, MA 02142), on June 8, 2024, 9 am - 5 pm EDT. About SAPA-NE SAPA (Sino-American Pharmaceutical Professionals Association) is one of the most active and largest Chinese-based biopharmaceutical ...
[Philadelphia, May 7-9, 2024] - Protheragen-ING, a pharmaceutical products supplier focused on innovative drug discovery and development, is pleased to announce its participation in the highly anticipated 2024 CPHI North America Conference. The event is scheduled to take place from May 7 to May 9, 2024, at the Pennsylvania Convention Center in East Philadelphia, Pennsylvania. Our booth number is ...
This cutting-edge technology promises to revolutionize tablet manufacturing by ensuring high-quality and consistent tablet production for pharmaceutical companies worldwide. ...
In recent years, the field of drug delivery has experienced significant advancements in the development of innovative delivery systems such as microspheres and microneedles. These advanced systems offer unique benefits, including enhanced drug stability, sustained release, and targeted delivery. However, the successful formulation and optimization of these delivery systems pose significant ...
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
Currently, CD Formulation is capable of conducting the following drug delivery services for pharmaceutical companies: Microneedle Technology Services Microneedle process development technology can ensure effective delivery of drugs to the medicinal site. ...
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the ...
Kurve’s patented Controlled Particle Dispersion® (CPD) technology, in side by side testing with infusions, is able to deliver up to 30x more medication directly to the brain than traditional intravenous or oral delivery methods can. ...
The Korea Health Industry Development Institute (KHIDI) announced on the 31st that it held the 'China Pharmaceutical Bio Investment Briefing (IR)' on the 20th, where domestic pharmaceutical companies introduced their technologies to Chinese investors. ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay has been elected to its board of directors as an independent director. ...
Panag will work with True North's product team to integrate this technology and develop a line of hemp-derived CBD formulations, for True North and its partners to commercialize through their existing distribution relationships in both the medical and recreational markets in Canada About the Technology In developing these products, the Panag ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generationiLink™ therapy designed to treat ...
The successful closing of this transaction demonstrates that Grand Pharma has completed the strategic layout in our cerebro-cardiovascular high-end medical devices sector. InnovHeart Saturn technology is one of the most promising TMVR technologies in the market. ...
She was previously the acting Chief Medical Officer and served on the board of Loxo Oncology (sold to Eli Lilly). She also served as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and CMO at Proteolix, Inc. ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia. ...
--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in ...